Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials

Lancet

Volumn 364, Issue 9437, 2004, Pages 858-868

  Fisher, Prof Bernard ^a,d   Jeong, Jong Hyeon ^b   Bryant, Prof John ^b   Anderson, Stewart ^b   Dignam, James ^b   Fisher, Prof Edwin R ^c   Wolmark, Prof Norman ^a  

^a NSABP Foundation Inc   (United States)

^b Biostatistical Center   (United States)

^c PA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLACEBO; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC THERAPY; TREATMENT FAILURE; TUMOR GROWTH; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECURRENCE; SURVIVAL RATE; TAMOXIFEN;

EID: 4544329012     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16981-X     Document Type: Article

References (34)

1. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 320:1989;479-484
2. Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. J Natl Cancer Inst Monogr. 11:1992;105-116
3. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 88:1996;1529-1542
4. Fisher B, Jeong J-H, Dignam J, Anderson S, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 30:2001;62-66
5. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 89:1997;1673-1682
6. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 294:1976;405-410
7. Efron B. Forcing a sequential experiment to be balanced. Biometrika. 58:1971;403-417
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170
10. Cox DR. Regression models and life tables. J R Stat Soc. 34:1972;187-200
11. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 19:2000;2595-2609
12. Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Statist Assoc. 83:1988;596-610
13. Kruskal WH, Wallis WA. Use of ranks in one criterion variance analysis. J Am Statist Assoc. 57:1952;583-621
14. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 8:1990;1005-1018
15. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol. 15:1997;1385-1394
16. International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 94:2002;1054-1065
17. Fisher B, Wickerham DL, Brown A, et al. Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes. J Clin Oncol. 1:1983;349-358
18. Fisher B, Redmond C, Wickerham DL, et al. Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res Treat. 3:1983;355-364
19. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1:1983;227-241
20. Fisher B. Laboratory and clinical research in breast cancer - a personal adventure: the David A Karnofsky memorial lecture. Cancer Res. 40:1980;3863-3874
21. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467
22. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 352:1998;930-942
23. McGuire WL, Horwitz KB, Pearson OH, Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer. 39:1977;2934-2947
24. Carbone PP, Tormey DC. Combination chemotherapy for advanced disease in breast cancer I. McGuire WL. Advances in research and treatment. 1977;165-216 Plenum Medical, New York
25. Lippman ME, Allegra JC, Thompson EB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med. 298:1978;1223-1228
26. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. In: Sommers SC, Rosen PP, eds. Pathology annual, part I, vol 15. New York: Appleton-Century-Crofts, 1980; 239-51.
27. Fisher ER, Osborne CK, McGuire WL, et al. Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat. 1:1981;37-41
28. Meyer JS, Rao BR, Stevens SC, White WL. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer. 40:1977;2290-2298
29. Fisher B, Fisher ER, Redmond C, Brown A. Tumor nuclear grade, estrogen receptor and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res Treat. 7:1986;147-160
30. Fisher ER, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project VIII: relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer. 51:1983;181-191
31. Fisher ER, Redmond C, Fisher B. Prognostic factors in NSABP studies of women with node-negative breast cancer. J Natl Cancer Inst Monogr. 11:1992;151-158
32. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 235:2002;10-26
33. Lundin J, Lundin M, Holli K, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol. 19:2001;28-36
34. Bryant J, Fisher B, Gündüz N, Costantino JP, Emir B. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 51:1998;239-253